Today's Challenges. Tomorrow's Solutions.

Strategic Solutions for Physical Medicine & Rehabilitation That Turn Functional Recovery Into Enterprise Value

Physiatry earns across an unusually broad base — office E/M, electrodiagnostics, interventional injections, buy-and-bill botulinum toxin, and therapy ancillary — and every one of those lines is under separate payer pressure. Fulcrum Health Partners advises PM&R groups, spine and pain platforms, IRF-affiliated organizations, and PE-backed investors on commercial rate strategy, procedure and drug reimbursement, and post-acute value-based design — so the full revenue base is captured, contracted, and defended.

Model Your Reimbursement Opportunity → Speak with a PM&R Advisor

$2.7B

Reimbursement Opportunity Identified

12,500+

Payer Contracts Reviewed

States Served

500+

Client Engagements

The PM&R Reimbursement Landscape

The Revenue Base Is Broad. The Pressure Is on Every Line of It.

Physiatry is one of medicine's most diversified professional P&Ls — and that diversity is both the opportunity and the exposure. The margin lives in the procedures you capture, the drug you buy and bill, and the therapy you own.

A single physiatry practice can bill office and consultative E/M, electrodiagnostics (EMG/NCS), interventional spine and joint injections, spasticity management with botulinum toxin under buy-and-bill, and therapy (PT/OT) as an ancillary line — each governed by its own coverage rules, edits, and payer policy. Electrodiagnostic complexity is routinely under-documented, injection reimbursement swings on site-of-service, and buy-and-bill economics turn on acquisition cost versus allowable. The result is a revenue base that is rich in aggregate but leaks quietly, line by line.

Layered on top are prior-authorization regimes and therapy medical-necessity thresholds signaled by the KX modifier, workers'-compensation and out-of-network dynamics, prosthetics, orthotics, and DME, and — for IRF-affiliated groups — the discipline of the IRF PPS and the 60% Rule. As orthopedics and pain platforms consolidate and post-acute shifts toward functional-outcome and value-based models, the same physiatrist can be worth dramatically different amounts depending on how the full base is coded, contracted, and defended. That is precisely where Fulcrum works.

* Illustrative composition. Replace with your confirmed figures before launch; reflects current CMS/MedPAC methodology and public payer data, 2024–2026.

Revenue Composition — Physiatry Professional Base (Illustrative)

Where PM&R margin is earned — and where it leaks

Office & consult E/M

Electrodiagnostics (EMG/NCS)

Interventional injections

Botulinum toxin (buy-and-bill)

Therapy (PT/OT) ancillary

The visit is one line of five. Fulcrum quantifies the full base — coded, contracted, and defended against leakage.

Distinct revenue lines in the physiatry professional base

60%

IRF PPS compliance threshold — the “60% Rule”

Modifier signaling medically necessary therapy above threshold

J-code

Botulinum toxin billed under buy-and-bill economics

Reimbursement Intelligence in Action

Your PM&R Economics, by Practice Profile

Fulcrum turns your claims, charge, and contract data into executive dashboards. Select a profile to explore a sample payer-mix and revenue view spanning E/M and the procedure, drug, and therapy lines that define physiatry.

Independent Physiatry / Outpatient · Payer Mix & Revenue Live Sample

Payer Mix (by professional charges)

Net Revenue by Payer — E/M vs. Procedures, Drug & Therapy

E/M professional net paymentsProcedures, injections, botulinum & therapy

* Illustrative sample dashboard. Fulcrum builds these from your practice-management, claims, charge, and contract data by CPT/HCPCS, payer, and contract.

Our PM&R Advisory Solutions

Advisory Organized Around the Economics You Manage

Not a service menu — the reimbursement problems that decide physiatry margin and enterprise value across every revenue line, and the strategy, analytics, and negotiation capabilities that resolve them.

01 The Challenge — You can't negotiate what you haven't benchmarked

Contract Assessment & Reimbursement Benchmarking

We digitize and normalize every payer contract and fee schedule, then benchmark your PM&R reimbursement — E/M, electrodiagnostics, injections, botulinum toxin, and therapy — against Medicare and against market using proprietary intelligence, quantifying exactly where you sit and what the opportunity is worth line by line.

Contract digitization

Fee schedule normalization

% of Medicare benchmarking

Electrodiagnostic & injection rate analysis

Buy-and-bill (ASP) benchmarking

Therapy & DME fee review

Site-of-service differential analysis

Revenue opportunity quantification

Contract performance scoring

02 The Challenge — Little leverage one contract at a time

Managed Care Negotiations & Strategy

We build the positioning, data, and negotiation strategy to improve commercial rates across E/M, procedures, drug, and therapy — and to secure workers'-comp and out-of-network terms that reflect the value physiatry actually delivers.

Commercial rate improvement

Contract renewals & redlining

MA & Medicaid managed care

Workers'-comp & OON strategy

Escalation & executive strategy

Network participation strategy

03 The Challenge — Decisions made without modeling the downside

Contract Modeling & Analytics

CPT- and HCPCS-level modeling that turns claims and contracts into scenario analysis, revenue forecasts, and site-of-service and buy-and-bill margin comparisons your executives can act on.

CPT/HCPCS-level modeling

Scenario & what-if analysis

Site-of-service margin modeling

Buy-and-bill drug margin analysis

Payer mix & revenue forecasting

Executive Power BI dashboards

04 The Challenge — Negotiating blind to what competitors are paid

Payer Transparency & Market Rate Intelligence

Federal Transparency in Coverage data has transformed the negotiating table. We mine machine-readable rate files to show what competing physiatry, spine, and pain groups are actually paid for the same codes — and arm your team with it.

Transparency in Coverage analysis

Competitor rate benchmarking

Procedure & drug rate positioning

Negotiation preparation

Peer comparison

Commercial opportunity sizing

05 The Challenge — Effort spread evenly across unequal payers

Covered Lives & Market Intelligence

We map covered lives, payer penetration, referral sources, and workers'-comp volume across your market so you prioritize the negotiations and service-line investments that move the most margin.

Covered-lives analysis

Payer penetration & market share

Referral & post-acute dynamics

Workers'-comp volume mapping

Employer & population trends

Commercial opportunity identification

06 The Challenge — Contract terms that aren't honored

Payer / Provider Disputes & Enforcement

When payers deny electrodiagnostics, bundle injections, challenge medical necessity, or restrict buy-and-bill, we lead the interpretation, escalation, and enforcement — turning contractual entitlement into collected revenue.

Contract interpretation

Payment & claims disputes

Bundling & medical-necessity challenges

Escalation support

Executive negotiation

Contract enforcement

07 The Challenge — Earned revenue that never arrives — or is clawed back

Underpayment / Overpayment Recovery & Revenue Integrity

Our analytics compare contracts, fee schedules, ASP-based allowables, and EOB/remittance data to detect variances in both directions — quantifying recoverable underpayments, defending against improper takebacks, and fixing the root cause so leakage stops.

Contract compliance auditing

Underpayment & variance detection

Overpayment / takeback defense

Automated EOB/remit analytics

Recovery & appeals strategy

Revenue integrity programs

The Forces Reshaping PM&R Economics

The Strategic Questions Every Physiatry Leader Now Faces

Beyond the fee schedule, these are the dynamics that decide PM&R margin across every revenue line — and where Fulcrum builds the strategy.

Site-of-Service & Injection Economics

How injection and procedure margin swings between office, ASC, and hospital outpatient settings — and how to contract and steer for the setting that protects reimbursement.

Prior Authorization & Therapy Medical Necessity

Managing prior-authorization burden and therapy thresholds signaled by the KX modifier, where documentation gaps convert directly into denials and takebacks.

Buy-and-Bill Botulinum-Toxin Margin

Protecting spasticity-management economics where acquisition cost, ASP-based allowables, and payer utilization policy determine whether the drug earns or erodes margin.

IRF PPS & the 60% Rule

Navigating inpatient rehabilitation facility medical direction, case-mix, and the compliance threshold that governs qualifying admissions and facility economics.

Consolidation with Ortho & Pain Platforms

Competing with — and evaluating alignment against — orthopedic, spine, and pain platforms and PE-backed rehabilitation groups now consolidating physiatry.

Value-Based & Functional-Outcome Models

Positioning for post-acute bundles and functional-outcome arrangements that reward recovery trajectory rather than procedure volume alone.

PM&R Reimbursement Calculator

See What a Fully Captured, Well-Contracted Base Is Worth

Model the annual uplift from three physiatry levers: capturing under-billed electrodiagnostic and injection procedures, adding therapy (PT/OT) ancillary contribution, and moving commercial rates toward optimized levels expressed as a percentage of Medicare.

Your Inputs

Enter approximate figures — nothing is stored or transmitted.

Annual commercial professional revenue

Electrodiagnostic & injection capture uplift (% of base)

Therapy (PT/OT) ancillary contribution (% of base)

Current commercial rate (% of Medicare)

Optimized commercial rate (% of Medicare) — 130%

Estimated annual reimbursement uplift

Adjust the inputs to model your opportunity.

Per $1M of commercial revenue

3-year cumulative

* Directional estimate for discussion only. Combines procedure/injection capture, therapy ancillary contribution, and commercial rate improvement; buy-and-bill drug margin, workers'-comp, and IRF economics are modeled separately. A Fulcrum analysis models your actual contracts, charges, and payer mix.

Client Outcomes

How Fulcrum Helps — And What It's Worth

Anonymized outcomes from Fulcrum engagements with physical medicine and rehabilitation groups and platforms.

Independent Physiatry Group

21%

commercial rate improvement

Situation: a physiatry group was paid well below market on electrodiagnostics and injections and had never benchmarked its contracts. Result: we repositioned the group on procedure-level data and renegotiated its top commercial payers, lifting blended commercial reimbursement without adding a single encounter.

Spine & Rehabilitation Platform

$3.8M

recovered procedure & drug revenue

Situation: bundled injection denials and buy-and-bill botulinum underpayments were quietly eroding margin across sites. Result: automated remit analytics isolated the variances, recovered the shortfall, and remediated the root-cause edits so the leakage stopped.

PE-Backed Rehab & Pain Group

8 pts

margin from contract harmonization

Situation: a multi-state platform carried a patchwork of legacy physiatry, therapy, and DME contracts ahead of a recapitalization. Result: we harmonized terms, aligned site-of-service strategy, and recovered systematic underpayments — lifting EBITDA before diligence.

Why PM&R Leaders Choose Fulcrum

The Advisor That Speaks Physiatry's Economic Language

Independent by design and fluent in the full physiatry base — E/M, electrodiagnostics, injections, buy-and-bill botulinum toxin, therapy, and post-acute — delivered by the people who do the work.

Independent Advisor

No networks, no downstream fees — only your economics.

Full-Base PM&R Fluency

Fluent across E/M, electrodiagnostics, injections, drug, and therapy.

Commercial Rate Benchmarking

Market and transparency data behind every ask.

CPT/HCPCS & Buy-and-Bill Analytics

Modeling down to the code, the drug, and the site of service.

National Payer Experience

Insight into payer policy and edits in every market.

IRF, Therapy & DME Insight

Command of the 60% Rule, KX thresholds, and ancillary lines.

Negotiation Leadership

Senior advisors at the table, not junior staff.

Data-Driven Support

Dashboards and intelligence that clarify the path.

Fulcrum Intelligence

Physical Medicine & Rehabilitation Insights & Analysis

Executive briefings on the forces moving physiatry economics — electrodiagnostic and injection reimbursement, buy-and-bill drug margin, therapy thresholds, IRF policy, and post-acute value.

Browse the full Fulcrum Insights library →

Explore PM&R Insights →